Changes to This Summary (06/26/2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text to state that bevacizumab, the humanized, antivascular, epithelial growth–factor monoclonal antibody, had a response rate in 5 of 16 patients who did not improve after the institution of highly active antiretroviral treatment and chemotherapy (cited Uldrick et al. as reference 20 and level of evidence 3iiiDiv).
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.